Elias Van De Vijver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elias Van De Vijver has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Christophe Ampe
Ghent University
3 shared publications - Hans Van Vlierberghe
Ghent University, Ghent, Belgium
3 shared publications - Marleen Van Troys
Ghent University
3 shared publications - Axl Van Alboom
Department of Industrial Systems Engineering and Product Design, Ghent University, Ghent, 9000, Belgium
2 shared publications - Klara Dewitte
Department of Biomolecular Medicine, Faculty Medicine and Health Care, Ghent University, Ghent, 9000, Belgium
2 shared publications - Delphine Burggraeve
Ghent University
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
SImBA-SiQuAl: Advancing High-Content High-Throughput Phenotypic Profiling of 3D Microtumours
Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research.
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSImBA-SiQuAl: Advancing High-Content High-Throughput Phenotypic Profiling of 3D Microtumours
Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research.
- Open Access
Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responses
Background and aims Therapeutic outcomes for advanced hepatocellular carcinoma remain inadequate, despite recent advances using immunotherapy. Long-term effectiveness of systemic therapies, including second-line multi-tyrosine kinase inhibitor sorafenib, is limited by resistance mechanisms and adverse effects. Upregulated deubiquitinase UCH-L1 is frequently correlated with poor prognosis in cancers. Here, we investigated the therapeutic potential of combining pharmacological UCH-L1-inhibition with sorafenib in HCC. Methods UCH-L1 expression was analysed in TCGA-LIHC data and patient-derived HCC tissues. Sorafenib and LDN57444 effects were evaluated in vitro in cytotoxicity and invasion assays. Gene and protein expression were examined by RT-qPCR, Western blotting and immunohistochemistry. In vivo efficacy of drug synergy was assessed in an orthotopic xenograft mouse HCC model. Results In silico data-analysis revealed significantly higher UCH-L1 levels in patient HCC tumours versus non-tumour, associated with reduced overall survival. Low-dose sorafenib upregulated UCH-L1 in HCC cell line Hep3B. Paradoxically, this also promoted invasiveness and sustained MEK1/2-ERK1/2-pathway activation. Combining low-dose sorafenib with LDN57444 produced strong synergistic cytotoxicity in vitro, reverted MAPK-activation and suppressed invasion. Consistently, at low sorafenib dose co-treatment with LDN57444 completely inhibited tumour growth of Hep3B xenografts and enhanced sorafenib efficacy. Conclusion LDN57444 sensitises HCC cells to low-dose sorafenib by reverting drug-induced pro-oncogenic signalling and thereby strongly synergises with sorafenib to enhance anti-tumour efficacy in a HCC mouse model. This presents UCH-L1 as a player in treatment-induced adaptive response and supports further exploring UCH-L1-targeting in combination with sorafenib as therapeutic avenue for advanced HCC.
Open AccessPharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responses
Background and aims Therapeutic outcomes for advanced hepatocellular carcinoma remain inadequate, despite recent advances using immunotherapy. Long-term effectiveness of systemic therapies, including second-line multi-tyrosine kinase inhibitor sorafenib, is limited by resistance mechanisms and adverse effects. Upregulated deubiquitinase UCH-L1 is frequently correlated with poor prognosis in cancers. Here, we investigated the therapeutic potential of combining pharmacological UCH-L1-inhibition with sorafenib in HCC. Methods UCH-L1 expression was analysed in TCGA-LIHC data and patient-derived HCC tissues. Sorafenib and LDN57444 effects were evaluated in vitro in cytotoxicity and invasion assays. Gene and protein expression were examined by RT-qPCR, Western blotting and immunohistochemistry. In vivo efficacy of drug synergy was assessed in an orthotopic xenograft mouse HCC model. Results In silico data-analysis revealed significantly higher UCH-L1 levels in patient HCC tumours versus non-tumour, associated with reduced overall survival. Low-dose sorafenib upregulated UCH-L1 in HCC cell line Hep3B. Paradoxically, this also promoted invasiveness and sustained MEK1/2-ERK1/2-pathway activation. Combining low-dose sorafenib with LDN57444 produced strong synergistic cytotoxicity in vitro, reverted MAPK-activation and suppressed invasion. Consistently, at low sorafenib dose co-treatment with LDN57444 completely inhibited tumour growth of Hep3B xenografts and enhanced sorafenib efficacy. Conclusion LDN57444 sensitises HCC cells to low-dose sorafenib by reverting drug-induced pro-oncogenic signalling and thereby strongly synergises with sorafenib to enhance anti-tumour efficacy in a HCC mouse model. This presents UCH-L1 as a player in treatment-induced adaptive response and supports further exploring UCH-L1-targeting in combination with sorafenib as therapeutic avenue for advanced HCC.
- Open Access
SImBA-SiQuAl: advancing high-content high-throughput phenotypic profiling of 3D microtumours
SUMMARY: Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research. MOTIVATION: 3D-microtumour assays such as spheroids and organoids are increasingly used in preclinical research. These assays generate rich phenotypic imaging data, but automated quantitative analysis remains a major bottleneck. This limits reproducibility, scalability, and broad adoption for large-scale, high-content phenomics studies. Moreover, it impedes comprehensively addressing biologically relevant phenotypic (heterogeneous) responses in e.g. perturbation studies. SImBA-SiQuAl ( S pheroid Im age B atch A nalysis - Si mba Qu antitative output A na l ysis) is developed to address this gap by providing an open-source, integrated workflow offering solutions in both the image processing and downstream analysis. Together, this enables in-depth quantitative analysis of 3D microtumour phenotypes across experimental settings.
Open AccessSImBA-SiQuAl: advancing high-content high-throughput phenotypic profiling of 3D microtumours
SUMMARY: Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research. MOTIVATION: 3D-microtumour assays such as spheroids and organoids are increasingly used in preclinical research. These assays generate rich phenotypic imaging data, but automated quantitative analysis remains a major bottleneck. This limits reproducibility, scalability, and broad adoption for large-scale, high-content phenomics studies. Moreover, it impedes comprehensively addressing biologically relevant phenotypic (heterogeneous) responses in e.g. perturbation studies. SImBA-SiQuAl ( S pheroid Im age B atch A nalysis - Si mba Qu antitative output A na l ysis) is developed to address this gap by providing an open-source, integrated workflow offering solutions in both the image processing and downstream analysis. Together, this enables in-depth quantitative analysis of 3D microtumour phenotypes across experimental settings.